Radioactive Source Market Size, Share, Growth and Industry Analysis, By Type (Mo-99, Co-60, Na-22, Co-57, Sr-90, I-131, Ir-192, Se-75, Kr-85, Am-241), By Application (Medical, Industrial, Agriculture, Scientific Research, And Others), Regional Insights and Forecast From 2026 To 2035

• 

  Download Free Sample to learn more about this report

RADIOACTIVE SOURCE MARKET OVERVIEW

The global radioactive source market is estimated to be valued at USD 1.25 Billion in 2026. The market is projected to reach USD 1.78 Billion by 2035, expanding at a CAGR of 4% from 2026 to 2035.

The radioactive source market covers sealed and unsealed radionuclides used in diagnostic imaging, cancer therapy, industrial radiography, sterilization, gauging, agriculture and laboratory research. Demand is shaped by half-life, specific activity, shielding needs and strict control over production, transport and disposal. Technetium-99m, the daughter product of Mo-99, is used in about 80% of nuclear medicine procedures, which keeps Mo-99 central to supply planning. Because Mo-99 has a half-life of 66 hours, reactor uptime and logistics define reliability. Co-60 and Ir-192 anchor industrial demand, while alpha emitters are reshaping research priorities across the radioactive source market.

The United States radioactive source market is shaped by a layered regulatory framework involving the Nuclear Regulatory Commission, the Department of Energy and agreement states. Hospitals, cancer centers and academic laboratories rely on dependable isotope supply, and domestic efforts to produce Mo-99 without highly enriched uranium continue to attract federal support. Industrial radiography firms, oil and gas service providers and sterilization operators depend on Ir-192 and Co-60 sources managed under strict licensing and tracking rules. Source security programs, including recovery of disused sources, address long-term risk. Radiopharmaceutical developers working on targeted therapy are strengthening demand for diverse isotopes and domestic production partnerships.

KEY FINDINGS

LATEST TRENDS

Use of New Detector Technologies to Increase the Market Growth

Alpha-emitting isotopes are the most visible shift in the radioactive source market. Actinium-225 and lead-212 attract biotechnology and pharmaceutical developers because alpha particles deliver intense energy over very short distances, which suits small tumors and micrometastases. Producers have responded with larger production capacity and supply agreements that link isotope makers to contract manufacturers. Another trend is the steady move to low-enriched uranium for Mo-99 production, which supports nonproliferation goals and has been completed at several major producers.

Linear accelerator and cyclotron routes are gaining attention because they reduce dependence on ageing research reactors. Technetium-99m has a half-life of 6 hours, so regional generator distribution and just-in-time logistics are being redesigned to lower the risk of missed deliveries. In the industrial segment, operators are funding reactor refurbishment to protect Co-60 availability, while digital source tracking, tamper-evident containers and remote handling tools improve security. Some irradiation users are testing X-ray alternatives, which encourages suppliers to emphasize source exchange programs, service contracts and safe end-of-life recovery.

Download Free Sample to learn more about this report

RADIOACTIVE SOURCE MARKET SEGMENTATION

By Type

Based on Type the global market can be categorized into Mo-99, Co-60, Na-22, Co-57, Sr-90, I-131, Ir-192, Se-75, Kr-85 and Am-241.

• Mo-99: Mo-99 accounts for 24% of the radioactive source market and is the parent of Tc-99m, the workhorse of diagnostic imaging. Its half-life of 66 hours demands rapid processing, packaging and air freight. Production relies on fission of uranium targets in research reactors, and the industry is converting to low-enriched uranium to reduce proliferation risk. Generator makers supply hospitals and radiopharmacies that elute Tc-99m daily for cardiac, bone and oncology scans. Diversification through new reactors, accelerators and alternative targets is a priority for health authorities.

• Co-60: Co-60 holds a 20% share and is the leading gamma source for sterilization, food irradiation and radiotherapy. Its half-life of 5.27 years gives users predictable decay and long source life. Most supply comes from activating cobalt-59 in power and research reactors, so reactor refurbishment schedules affect availability. Medical device sterilizers favor Co-60 irradiators because the gamma rays penetrate dense packaging evenly. Teletherapy units and gamma knife systems also use sealed Co-60 sources, and source recovery services add recurring value for suppliers.

• Na-22: Na-22 represents a 5% share and serves niche but technically important uses. It is a positron emitter with a half-life of 2.6 years, making it a common choice for calibrating PET scanners and for positron annihilation spectroscopy in materials science. Sealed point sources also appear in quality assurance phantoms and academic laboratories. Cyclotron production keeps supply limited and customized. Demand follows PET system installations and research funding, and suppliers compete on encapsulation quality, activity accuracy and traceable calibration certificates.

• Co-57: Co-57 also commands a 5% share and is valued for its gamma emissions and half-life of 272 days. Reference sources are widely used to calibrate gamma cameras, dose calibrators and spectrometers, and the isotope supports Mössbauer spectroscopy in research. Cyclotron production by proton bombardment of nickel targets limits the number of qualified suppliers. Demand grows with each new SPECT system and nuclear pharmacy that needs flood sources and calibration standards. Producers with accredited laboratories and strong quality systems hold an advantage in this compact segment.

• Sr-90: Sr-90 holds a 7% share and is a pure beta emitter with a half-life of 28.8 years. Its long life supports thickness gauges for paper, plastic and metal foil, static eliminators and ophthalmic applicators. The daughter isotope Y-90 links this chain to cancer therapy through radioembolization. Sr-90 is a fission product recovered from spent fuel streams, so availability depends on nuclear programs rather than dedicated production. Strict control follows from its biological uptake in bone, and decommissioning of legacy devices remains an active service market.

• I-131: I-131 accounts for an 11% share and is widely used to treat hyperthyroidism and thyroid cancer. Its half-life of 8 days balances effective therapy with manageable logistics, and it emits beta particles for treatment and gamma rays for imaging. It is produced from uranium fission or neutron irradiation of tellurium and supplied as oral capsules or solutions. Rising thyroid disorder diagnoses and outpatient therapy protocols support volumes, while partnerships to expand capsule supply are improving access across Europe.

• Ir-192: Ir-192 holds a 10% share and is the dominant source for industrial gamma radiography. With a half-life of 74 days, it delivers high specific activity in compact capsules, allowing inspection of welds in pipelines, pressure vessels and aircraft components. Production uses neutron irradiation of iridium-191, and frequent source replacement creates recurring demand. Brachytherapy forms a smaller medical outlet. Infrastructure construction, oil and gas maintenance and power plant outages influence orders, while competition from digital X-ray and ultrasonic testing shapes source exchange programs.

• Se-75: Se-75 represents a 5% share and complements Ir-192 in industrial radiography. Its half-life of 120 days and gamma energy profile suit inspection of thin-wall pipes and welds where good image contrast matters. Operators favor it on pipeline projects because lower energy emission reduces shielding needs. Production uses neutron irradiation of enriched selenium-74, so supply is concentrated among a few reactor operators and source fabricators. Demand follows construction cycles in energy, shipbuilding and chemical processing.

• Kr-85: Kr-85 holds a 6% share and is a beta-emitting noble gas with a half-life of 10.76 years. Industrial gauging for paper, plastics and rubber uses it to measure thickness and density, and it also supports leak detection. Because it is a gas, it is encapsulated in sealed sources that must meet rigorous leak testing standards. Supply originates mainly from nuclear fuel reprocessing, linking availability to a limited number of facilities. Demand remains stable in mature manufacturing sectors, while non-nuclear sensors temper expansion.

• Am-241: Am-241 accounts for a 7% share and is best known in ionization smoke detectors. With a half-life of 432 years, it offers stable alpha emission over the life of a device. It is also used in industrial moisture and density gauges, well logging and static control equipment. Production occurs through the decay of Pu-241 in reprocessed plutonium, so supply depends on civilian fuel cycles. Photoelectric detectors are gaining ground in some markets, but commercial buildings and plants still specify ionization alarms for fast flame detection.

By Application

Based on Application the global market can be categorized into Medical, Industrial, Agriculture, Scientific Research and Others.

• Medical: Medical applications lead with a 44% share, covering diagnostic imaging, radionuclide therapy, brachytherapy and equipment calibration. Tc-99m derived from Mo-99 is used in about 80% of nuclear medicine procedures, giving hospitals a dependable imaging workhorse for cardiac, bone and cancer studies. Therapeutic isotopes such as I-131, Lu-177, Y-90 and Ac-225 are expanding treatment options for thyroid disease, neuroendocrine tumors and prostate cancer. Investments in PET and SPECT infrastructure and radiopharmacy networks support volume growth, and reliable logistics are a decisive competitive factor.

• Industrial: Industrial applications hold a 31% share and include radiography, gauging, well logging, sterilization and static elimination. Ir-192 and Se-75 sources inspect welds in pipelines, boilers and aerospace parts, while Co-60 irradiators sterilize medical devices and packaged goods. Sr-90, Kr-85 and Am-241 sources provide thickness, density and level measurement in paper, plastic, steel and mining plants. Demand follows infrastructure spending, maintenance cycles and the rise of single-use medical products, and suppliers add source exchange, recovery and training services.

• Agriculture: Agriculture holds an 8% share and covers pest sterilization, food irradiation, crop breeding and nutrient tracing. Co-60 gamma sources support sterile insect programs, which suppress pests such as fruit flies and screwworms without chemical sprays. Irradiation also extends the shelf life of spices, grains and fresh produce and helps meet phytosanitary requirements for trade. Radioisotope tracers help researchers study fertilizer uptake and soil moisture, and gamma mutation breeding has produced improved crop varieties. Public acceptance, labeling rules and trade standards shape adoption.

• Scientific Research: Scientific research accounts for an 11% share, spanning physics, chemistry, materials science, environmental studies and radiopharmaceutical development. Universities and national laboratories use Co-57 for Mössbauer spectroscopy, Na-22 for positron annihilation studies and Am-241 for detector calibration. Tracer studies help scientists examine reaction pathways, groundwater flow and sediment dating. Growth in alpha therapy research is raising demand for Ac-225 and Pb-212 in preclinical programs. Small batches carry premium pricing and often seed later commercial adoption in medical and industrial markets.

• Others: Other applications represent a 6% share and include security screening, environmental monitoring, calibration services, education and consumer products. Am-241 powers ionization smoke detectors installed in homes and commercial buildings, while sealed check sources support radiation detection training for emergency responders and customs officers. Kr-85 serves as an atmospheric tracer for nuclear facility monitoring. Calibration laboratories need certified reference sources to keep survey meters and portal monitors accurate. This segment is small but resilient because it depends on compliance and public safety programs.

MARKET DYNAMICS

Driving Factor

Rising demand for nuclear medicine diagnostics and targeted therapy.

Diagnostic imaging and radionuclide therapy remain the strongest growth engines for the radioactive source market. Technetium-99m supports about 80% of nuclear medicine procedures, and each procedure depends on a steady flow of Mo-99 from reactors and processing plants. Ageing populations, higher cancer incidence and wider access to cardiac and bone imaging are raising scan volumes in mature and emerging health systems. Therapeutic isotopes such as I-131, Lu-177 and Ac-225 are widening the customer base to include biotechnology firms and specialty pharmacies. Hospitals are also adding PET and SPECT capacity, which lifts demand for generators, calibration sources and contract manufacturing services.

Driver Impact Analysis*

Restraining Factor

Stringent regulation and licensing requirements.

Strict regulation slows capital deployment and market entry across the radioactive source market. Producers, distributors and end users must obtain licenses, maintain accountability records and comply with transport rules that differ by country. Source security programs require background checks, tracking systems and secure storage, which raise operating costs for small hospitals, laboratories and inspection firms. Licensing of reactors, processing hot cells and waste facilities can take years, delaying capacity additions even when demand is clear. Carrier refusals, airline restrictions and customs delays further complicate shipments of short-lived isotopes, so smaller suppliers often depend on partnerships with established licensed operators.

Restraint Impact Analysis*

Growth of alpha emitters and theranostics.

Opportunity

Targeted alpha therapy is opening a fresh growth path for the radioactive source market. Isotopes such as Ac-225 and Pb-212 are moving from preclinical studies toward commercial supply, creating demand for new production routes, purification technology and shielded manufacturing space. Theranostic pairs, which combine a diagnostic isotope with a therapeutic one, encourage suppliers to offer broader portfolios and integrated development services. Contract manufacturers are adding radiopharmaceutical capacity, giving smaller biotechnology firms access to isotopes without building plants.

Fragile supply chains and short half-lives.

Challenge

Supply reliability is the most persistent challenge in the radioactive source market. Mo-99 has a half-life of 66 hours, so inventory cannot be stockpiled and any unplanned reactor shutdown quickly reaches hospitals. A small number of ageing research reactors and processing facilities provide much of the world supply, so maintenance outages create shortages. Replacement capacity requires heavy capital, long licensing timelines and skilled nuclear personnel who are difficult to recruit.

• Download Free Sample to learn more about this report

•  

RADIOACTIVE SOURCE MARKET REGIONAL INSIGHTS

• North America

North America holds a 34% share of the radioactive source market, the largest among regions. The United States and Canada operate dense nuclear medicine networks where Tc-99m supports about 80% of imaging procedures, sustaining demand for Mo-99 generators. Canada is the center of Co-60 supply, and Nordion holds a 25-year renewal of its Class 1B nuclear substance processing facility license while supporting refurbishment at Ontario reactors. The United States adds demand through industrial radiography, oil and gas services, sterilization plants and radiopharmaceutical start-ups. Federal programs promote Mo-99 production without highly enriched uranium. Regulatory clarity, strong reimbursement and large hospital systems keep the region at the front.

• Europe

Europe accounts for a 28% share and is shaped by a strong research reactor base, advanced radiopharmaceutical companies and harmonized regulation. NRG operates the High Flux Reactor in Petten, and IRE in Belgium has moved Mo-99 production to low-enriched uranium while building a radiopharmaceutical contract manufacturing facility in Fleurus. Germany and the Czech Republic are important for alpha emitter development, with Eckert & Ziegler and a Czech institute scaling Ac-225 production. Polatom in Poland supplies reactor-produced radioisotopes and radiopharmaceuticals to regional customers. Demand is anchored by cardiology imaging, thyroid therapy and industrial radiography in energy and automotive sectors.

• Asia Pacific

Asia Pacific captures a 25% share and is the fastest-growing region as healthcare access and industrial capacity expand. Australia produces Mo-99 from low-enriched uranium targets at the OPAL reactor, and ANSTO is expanding capacity at Lucas Heights to serve global generator makers. India relies on the Board of Radiation and Isotope Technology for Co-60, I-131 and Ir-192 sources. China Isotope & Radiation Corporation supplies sealed sources and isotopes to hospitals, irradiation plants and industrial users, while Curium has set up a Shanghai entity to advance therapeutic radiopharmaceuticals. Rising cancer screening and food irradiation lift demand regionwide.

• Middle East & Africa

Middle East & Africa holds a 7% share, supported by isotope production in South Africa and growing medical infrastructure in the Gulf. NTP Radioisotopes, a subsidiary of the South African Nuclear Energy Corporation, was the earliest major Mo-99 producer to convert its entire process to low-enriched uranium, strengthening its standing with international generator makers. Gulf countries are building cancer centers, PET facilities and sterilization plants, increasing imports of generators and sealed sources. Industrial radiography demand follows oil, gas and mining activity, while capacity gaps in many African nations make regional cooperation and technical assistance important.

• Rest of the World

Rest of the World holds a 6% share, led by Latin America, where Argentina, Brazil and Mexico anchor demand. Argentina has long exported reactor-produced radioisotopes and is building the RA-10 multipurpose reactor, while Brazil is investing in a new multipurpose reactor to reduce Mo-99 imports. Mexico uses irradiator technology in its sterile insect program, with Nordion expertise supporting efforts to control the New World screwworm. Hospitals are adding SPECT and PET systems, and mining and energy projects sustain radiography demand. Import dependence and customs delays remain obstacles to wider access.

KEY INDUSTRY PLAYERS

The competitive landscape of the radioactive source market combines state-linked reactor operators, specialized processors and integrated radiopharmaceutical companies. Established vendors such as Curium Pharma, Nordion, NTP Radioisotopes, ANSTO, IRE and NRG control reactor access, processing know-how and long-term supply contracts. Eckert & Ziegler Strahlen differentiates through isotope products, sealed sources and contract manufacturing, while Mayak, Polatom, China Isotope & Radiation Corporation and the Board of Radiation and Isotope Technology serve regional customers. Strategies include low-enriched uranium conversion, capacity expansion, generator supply partnerships, alpha emitter development and source recovery services.

LIST OF TOP RADIOACTIVE SOURCE COMPANIES

• NRG
• Mayak
• NTP Radioisotopes
• ANSTO
• Nordion
• IRE
• Curium Pharma
• Eckert & Ziegler Strahlen
• China Isotope & Radiation Corporation (CIRC)
• Polatom
• Board of Radiation and Isotope Technology

LEADER INSIGHTS

• Eckert & Ziegler: Dr. Harald Hasselmann, Chief Executive Officer of Eckert & Ziegler SE, said the company sees itself as a dependable enabler for the radiopharmaceutical industry. He described the lead-212 partnership with Thor Medical as a way to support the growing number of biotech and pharmaceutical developers pursuing new alpha therapy options. His comments point to rising customer demand for isotope supply and a strategy of becoming an integrated, end-to-end provider. (Published: May 28, 2026 | Source: https://live.deutsche-boerse.com)

• Curium Pharma: Ciril Faia, CEO of Curium International, said the plan for a second cyclotron investment in Romania reflects the company’s confidence in the country’s potential. He framed it as a long-term commitment to widening access to essential nuclear medicine services across the region. The added capacity is intended to strengthen PET imaging supply in Northern Romania and neighboring markets, which signals continued regional expansion in diagnostic demand. (Published: July 30, 2026 | Source: https://www.curiumpharma.com)

• Nordion: Riaz Bandali, President of Nordion, emphasized that Cobalt-60 is essential to the safety of the healthcare industry and that Ontario Power Generation has been a trusted supply partner for more than 50 years. His remarks on the refurbished Darlington Unit 4 reactor highlight ongoing investment to keep sterilization customers worldwide supplied with Cobalt-60. They also show the company’s focus on long-term supply continuity. (Published: February 24, 2026 | Source: https://www.nordion.com)

INVESTMENT ANALYSIS AND OPPORTUNITIES

Investment in the radioactive source market is concentrating on supply security, alpha emitter capacity and radiopharmaceutical manufacturing. Producers are funding reactor refurbishment, hot cell construction, cyclotron additions and low-enriched uranium conversion to protect customers from outages. Contract manufacturing facilities attract capital because biotechnology firms need isotope supply and production in one place. Opportunities also exist in source recovery, disposal services and digital tracking, where regulation creates recurring demand. Emerging regions offer room for sterilization plants and nuclear medicine centers. Since Mo-99 has a half-life of 66 hours, regional processing hubs near hospital clusters offer attractive logistics returns.

NEW PRODUCT DEVELOPMENT

Innovation in the radioactive source market centers on higher yield targets, new isotopes and safer source designs. ANSTO has introduced cylindrical, porous and reusable Mo-99 targets that raise output per irradiation, helping producers get more from existing reactor capacity. Eckert & Ziegler and a Czech nuclear physics institute have moved Ac-225 into larger scale continuous production, expanding clinical access to alpha therapy. Curium has returned Tl-201 injection to the United States market, restoring a cardiac imaging option. Suppliers are also developing low-enriched uranium generators, linear accelerator targets and improved encapsulation that extends source life and simplifies recovery.

FIVE RECENT DEVELOPMENTS

• January 2026: IRE selects Lemer Pax to equip shielded hot cells for new Fleurus contract manufacturing facility. IRE chose a French radiation protection specialist to equip its Belgian radiopharmaceutical contract manufacturing site, expanding production capability through shielded hot cell technology for customers.

• February 2026: Eckert & Ziegler and UJF scale up Actinium-225 production for clinical radiopharmaceutical supply. Eckert & Ziegler moved its joint initiative into larger scale manufacturing to strengthen Ac-225 supply for targeted alpha therapy through facilities in Řež and Braunschweig.

• February 2026: Nordion supports Ontario reactor refurbishment projects to secure long-term Co-60 supply. Nordion is investing alongside Ontario Power Generation in reactor refurbishment projects to safeguard long-term Co-60 availability for global sterilization and medical customers through irradiator expertise.

• February 2026: ANSTO unveils reusable porous cylindrical Mo-99 targets that increase production yield. ANSTO introduced a reusable porous cylindrical target design to raise Mo-99 yield, improving efficiency and supply capacity using its reactor irradiation and radiochemical processing capabilities.

• July 2026: Curium announces immediate return of Thallous Chloride Tl-201 injection to United States cardiac imaging market. Curium Pharma, working with nuclear cardiology leaders, restored Tl-201 supply to the United States, securing cardiac imaging access through its SPECT radiopharmaceutical manufacturing and distribution.

REPORT COVERAGE

This report covers the global radioactive source market by type, application and region. Type coverage includes Mo-99, Co-60, Na-22, Co-57, Sr-90, I-131, Ir-192, Se-75, Kr-85 and Am-241, while application coverage spans medical, industrial, agriculture, scientific research and others. Mo-99 leads the type view at 24%, and North America leads the regional view at 34%. The study profiles NRG, Mayak, NTP Radioisotopes, ANSTO, Nordion, IRE, Curium Pharma, Eckert & Ziegler Strahlen, China Isotope & Radiation Corporation, Polatom and the Board of Radiation and Isotope Technology, and examines drivers, restraints, opportunities, challenges, trends, investments and product development.